Free Republic

Two Covid-19 antibody therapies are no longer recommended by the World Health Organisation (WHO), as Omicron and the variant's latest offshoots have likely rendered them obsolete. The two therapies - which are designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus' ability to infect cells - were some of the first medicines developed early in the pandemic. The virus has since evolved, and mounting evidence from lab tests suggests the two therapies - sotrovimab, as well as casirivimab-imdevimab - have limited clinical activity against the latest iterations of the virus.

The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's (REGN.O) COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

New Delhi -- At a time when the country is passing through the second wave of Covid-19, Delhi-based Sir Gangaram Hospital claims that monoclonal antibody can be a game changer with its better hold on the deadly pandemic. As per the hospital, the monoclonal antibodies will change the scenario of Covid-19 pandemic very soon. The healthcare facility came with new findings after treatment of two patients recently at its centre by successfully using monoclonal antibody which showed fast progression of symptoms within first seven days and changed the outcome. A 36-year-old healthcare worker with high grade fever, cough, myalgia, severe...